NEUROCRINE BIOSCIENCES INC (NBIX) earnings date

Nasdaq · Large cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 34 days, typically, give or take 4 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Mon, Nov 2, 2026after close 33 8-K
Q2 FY2026Thu, Jul 30, 2026after close 30 8-K
Q1 FY2026Tue, May 5, 2026after close 35 8-K
Q4 FY2025Wed, Feb 11, 2026after close 42 8-K
Q3 FY2025Tue, Oct 28, 2025after close 28 8-K
Q2 FY2025Wed, Jul 30, 2025after close 30 8-K
Q1 FY2025Mon, May 5, 2025after close 35 8-K
Q4 FY2024Thu, Feb 6, 2025after close 37 8-K

What they guided beta

Q3 FY2026 "Document Exhibit 99.1 Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results Total Third-Quarter 2026 Revenue Grew 41% Year-Over-Year to $1.1 Billion INGREZZA ® (valbenazine) 2026 Net Sales Guidance Raised to $2.9 to $2.925 Billion SAN DIEGO , Nov. 2, 2026 – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the third quarter ended September 30, 2026." exhibit
Q3 FY2026 "INGREZZA full year 2026 guidance was increased from a range of $2.825 billion to $2.875 billion up to $2.9 billion to $2.925 billion." exhibit
Q3 FY2026 "Full Year 2026 Financial Guidance (dollars in millions) Prior Updated INGREZZA Net Product Sales 1 $2,825 - $2,875 $2,900 - $2,925 GAAP R&D 2 $1,275 - $1,325 No Change Non-GAAP R&D 2, 3 $1,140 - $1,190 No Change IPR&D 4 $23 $34 GAAP SG&A 5 $1,575 - $1,600 $1,540 - $1,560 Non-GAAP SG&A 3, 5 $1,325 - $1,350 $1,290 - $1,310 GAAP Amortization of Acquired Intangible Assets 6 $85 - $90 No Change 1." exhibit
Q3 FY2026 "SG&A guidance reflects expense for ongoing commercial initiatives, including the recent expansion of our sales teams in Q1 2026, supporting INGREZZA growth and the launch of CRENESSITY and VYKAT XR. 6." exhibit
Q3 FY2026 "These statements include, but are not limited to, statements related to: our business strategy, objectives, and future development plans; the benefits to be derived from our products and product candidates; the value our products and/or our product candidates may bring to patients; the continued success of INGREZZA; successfully commercializing CRENESSITY and VYKAT XR; our financial and operating performance, including our future revenues, expenses, or profits; our full year 2026 financial guidance; our acquisition of Soleno Therapeutics, including the prospective benefits of the acquisition, " exhibit
Q2 FY2026 "Document Exhibit 99.1 Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results Total Second-Quarter 2026 Revenue Grew 39% Year-Over-Year to $959 Million INGREZZA ® (valbenazine) 2026 Net Sales Guidance Raised to $2.825 to $2.875 Billion Acquisition of Soleno Therapeutics Completed in May 2026 SAN DIEGO , July 30, 2026 – Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the second quarter ended June 30, 2026." exhibit
Q2 FY2026 "INGREZZA full year 2026 guidance was increased from a range of $2.7 billion to $2.8 billion up to $2.825 billion to $2.875 billion." exhibit
Q2 FY2026 "Full Year 2026 Financial Guidance (dollars in millions) Prior Updated INGREZZA Net Product Sales 1 $2,700 - $2,800 $2,825 - $2,875 GAAP R&D 2 $1,200 - $1,250 $1,275 - $1,325 Non-GAAP R&D 2, 3 $1,110 - $1,160 $1,140 - $1,190 IPR&D 4 $20 $23 GAAP SG&A 5 $1,375 - $1,400 $1,575 - $1,600 Non-GAAP SG&A 3, 5 $1,240 - $1,265 $1,325 - $1,350 GAAP Amortization of Acquired Intangible Assets 6 Not applicable $85 - $90 1." exhibit
Q2 FY2026 "SG&A guidance reflects expense for ongoing commercial initiatives, including the recent expansion of our sales teams in Q1 2026, supporting INGREZZA growth and the launch of CRENESSITY and VYKAT XR. 6." exhibit
Q2 FY2026 "These statements include, but are not limited to, statements related to: our business strategy, objectives, and future development plans; the benefits to be derived from our products and product candidates; the value our products and/or our product candidates may bring to patients; the continued success of INGREZZA; successfully commercializing CRENESSITY and VYKAT XR; our financial and operating performance, including our future revenues, expenses, or profits; our full year 2026 financial guidance; our acquisition of Soleno Therapeutics, including the prospective benefits of the acquisition, " exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/NBIX
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/NBIX

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

NBIX earnings date badge

HTML

<a href="https://veritasdata.dev/company/NBIX/"><img src="https://veritasdata.dev/embed/NBIX.svg" alt="NBIX earnings date" width="240" height="56"></a>

Markdown

[![NBIX earnings date](https://veritasdata.dev/embed/NBIX.svg)](https://veritasdata.dev/company/NBIX/)

Script

<script async src="https://veritasdata.dev/embed/NBIX.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/NBIX"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.